|
|
Volumn 5, Issue 10, 2008, Pages 606-607
|
|
Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction-but at what cost to Medicare?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANGIOTENSIN RECEPTOR ANTAGONIST;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
AGED;
ARTICLE;
COHORT ANALYSIS;
COMPUTER MODEL;
COMPUTER SIMULATION;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
HEALTH CARE POLICY;
HEART INFARCTION;
HUMAN;
MEDICARE;
OUTCOME ASSESSMENT;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
QUALITY ADJUSTED LIFE YEAR;
SECONDARY PREVENTION;
ADRENERGIC BETA-ANTAGONISTS;
AGED;
ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
ANTILIPEMIC AGENTS;
ASPIRIN;
CARDIOVASCULAR AGENTS;
COMPUTER SIMULATION;
COST SAVINGS;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
DRUG THERAPY, COMBINATION;
HUMANS;
INSURANCE, PHARMACEUTICAL SERVICES;
MEDICARE;
MODELS, ECONOMIC;
MYOCARDIAL INFARCTION;
PATIENT COMPLIANCE;
QUALITY-ADJUSTED LIFE YEARS;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 54849141600
PISSN: 17434297
EISSN: 17434300
Source Type: Journal
DOI: 10.1038/ncpcardio1309 Document Type: Article |
|
Times cited : (2)
|
|
References (6)
|
